/transparent-payments-to-healthcare-professionals_feature.jpg
Transparent Payments to Healthcare Professionals

Across Europe the pharmaceutical industry has committed to disclose the payments that it has made to healthcare professionals (HCPs) and organizations (HCOs) through adoption of the European Pharmaceutical Industry's HCP/HCO Disclosure Code.

The very best clinical practice requires input and expertise from many groups: clinicians; patient organisations; academics; healthcare organisations; and those that discover and manufacture new medicines and medical technology. Collaboration between all of these important experts results in three main benefits:

  • Making new medicines possible in the first place;
  • Providing vital health education to ensure that medicines are used appropriately; and
  • Capturing real life insights into current treatments and understanding unmet medical needs.

It's important that these relationships are managed transparently to help demonstrate that the over-riding objective is to keep patients at the centre of our collective efforts. At Lilly, we value our relationship with HCPs and HCOs and fully support the European Federation of Pharmaceutical Industries and Association's (EFPIA's) commitment to publishing the details of payments and transfers of value made to them. These data are being published on an individual basis beginning 2016 and will be updated annually.

About the Code

The EFPIA Disclosure Code (approved in June 2013) requires all EFPIA member companies (those within and outside of the European Union) to disclose: fee-for-service and consultancy payments as well as reimbursed expenses for other activities such as serving on an advisory board; coverage of costs for HCPs' participation in medical education events including registration fees, necessary travel and accommodation; research and development transfers of value; and grants and donations made to HCOs.

Data privacy requires companies to acquire consent from the HCP for the individual disclosure of his/her name with associated transfers of value. If the HCP does not grant his/her consent for the individual disclosure, Lilly will report the associated payments and transfers of value in aggregate, under an unnamed category. Consent must also be collected from an HCO in some countries.

Please consult EFPIA's website for additional information on the Code, and direct any questions specific to Lilly's implementation of the Code to EU_Corporate@lilly.com.

Below are links to our reports for each country publishing data in accordance with the EFPIA Disclosure Code and methodological notes that describe Lilly's methods for meeting the requirements outlined by each country (countries begin reporting on May 31 with all countries reporting by June 30, 2016). Please note that in some countries data from all EFPIA member companies are published centrally and in these cases the link will take you to a third party website. Lilly provides this information in accordance with the EFPIA Disclosure Code and in the spirit of greater transparency. We ask that visitors do not use this information for alternative purposes (click here to read our letter of certification).

HCP/HCO Disclosure ReportMethodological Notes
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czech Republic
Estonia
Finland
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Sweden
Switzerland
Ukraine
United Kingdom